Victoza (liraglutide) works by mimicking a natural gut hormone called GLP-1, which your body releases after eating to help regulate blood sugar. The drug is 97% identical to the GLP-1 your body already makes, but it lasts much longer, allowing it to be injected just once a day. It lowers blood sugar through several pathways at once: boosting insulin, suppressing a competing hormone, slowing digestion, and reducing appetite.
How Victoza Mimics a Natural Hormone
When you eat, your small intestine releases GLP-1, a hormone that signals your pancreas to produce insulin. The problem is that natural GLP-1 breaks down in minutes. Victoza is an engineered version that sticks around much longer in the bloodstream, giving it time to work throughout the day with a single injection.
Once injected, liraglutide binds to the same receptors on your pancreas that natural GLP-1 would. This triggers a chain reaction inside insulin-producing beta cells, ultimately pushing them to release more insulin. The key detail: this insulin release is glucose-dependent, meaning it ramps up when your blood sugar is high and dials back when it’s normal. That built-in safety mechanism makes dangerously low blood sugar (hypoglycemia) less likely compared to some older diabetes medications that push insulin out regardless of what your blood sugar is doing.
The Glucagon Connection
Insulin isn’t the whole story. Your pancreas also produces glucagon, a hormone that tells your liver to dump stored sugar into your bloodstream. In type 2 diabetes, glucagon is often inappropriately elevated after meals, flooding your blood with extra glucose at exactly the wrong time. Victoza suppresses this glucagon surge. In studies of patients eating normal meals, glucagon levels dropped significantly within 15 to 45 minutes after eating while on liraglutide. The combination of more insulin and less glucagon is what makes the drug effective at pulling blood sugar down after meals and between them.
Slowing Digestion and Reducing Appetite
Victoza also slows the rate at which food leaves your stomach, particularly in the first hour after a meal. At the 3.0 mg dose (used for weight management, not the diabetes dose), gastric emptying in that first hour was reduced by about 23% compared to placebo. Even at the lower 1.8 mg diabetes dose, a measurable slowing occurs. This matters because when food enters your small intestine more gradually, the resulting blood sugar spike is smaller and more manageable.
The appetite effects are significant too. Patients on liraglutide report increased feelings of fullness and satiety after eating, along with reduced hunger between meals. In clinical testing, people on the drug ate roughly 16% fewer calories when given unlimited access to food. This wasn’t about willpower. The drug appears to act on appetite-regulating pathways in the brain, making you genuinely less hungry. Weight loss from Victoza is driven by this reduced appetite and lower calorie intake rather than any change in how many calories your body burns at rest.
What It Does for Blood Sugar Numbers
In real-world use across multiple studies, Victoza typically lowers HbA1c (a measure of average blood sugar over roughly three months) by 0.9% to 2.2% within the first six months. To put that in perspective, getting HbA1c below 7% is the standard treatment target, and between 29% and 65% of patients on liraglutide reached that goal. The range is wide because results depend on starting blood sugar levels, dose, diet, and whether other medications are being used alongside it.
Cardiovascular Benefits
A large clinical trial called LEADER found that Victoza reduced the risk of major cardiovascular events (heart attack, stroke, or cardiovascular death) by 13% in people with type 2 diabetes who already had high cardiovascular risk. This was a meaningful finding because heart disease is the leading cause of death in people with type 2 diabetes, and not all blood sugar medications offer this protection. The cardiovascular benefit is one reason Victoza is sometimes preferred over other options for patients with existing heart disease or multiple risk factors.
How the Dosing Works
Victoza is a once-daily injection given under the skin of the abdomen, thigh, or upper arm. You start at 0.6 mg daily for the first week, which is not a treatment dose. It exists solely to let your body adjust and reduce the chance of stomach-related side effects. After that first week, you move up to 1.2 mg. If your blood sugar still isn’t controlled well enough after at least another week, your dose can be increased to the maximum of 1.8 mg. You can take it at any time of day, with or without food, though sticking to the same time each day helps maintain steady levels.
Common Side Effects
The most frequent side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, and indigestion. Nausea is the most common complaint and tends to be worst during the first few weeks as your body adjusts, which is why the dose is increased gradually. For most people, these symptoms ease over time. Higher doses produce more nausea, which is consistent with how the drug works. By slowing your stomach, it can leave you feeling uncomfortably full or queasy, especially after large meals. Eating smaller portions often helps.
Victoza can also slightly increase resting heart rate in some people with type 2 diabetes, something your doctor may monitor.
The Thyroid Warning
Victoza carries the FDA’s most serious warning (a boxed warning) related to thyroid tumors. In animal studies, liraglutide caused thyroid C-cell tumors in rats and mice at doses relevant to human use, and the risk increased with higher doses and longer treatment. Whether this translates to humans is unknown, and no definitive link to thyroid cancer in people has been established. However, the drug is not prescribed to anyone with a personal or family history of medullary thyroid carcinoma or a condition called Multiple Endocrine Neoplasia syndrome type 2. If you notice a lump in your neck, difficulty swallowing, or persistent hoarseness while taking Victoza, those symptoms warrant prompt medical attention.